CD-RAP is viewed as a promising candidate for cartilage regeneration in indications such as chondral defects and osteoarthritis.

Pfizer will obtain a worldwide, exclusive license to develop and commercialize Scil Technology’s cartilage-specific growth factor CD-RAP. Scil is eligible for upfront and milestone payments of approximately $250 million. The company will also receive royalties on any products that may be commercialized under this agreement.


CD-RAP is a polypeptide that has been shown to play a crucial role during cartilage formation in embryonic development and in the matrix stimulation of chondrocytes in adult animals, according to Scil. Furthermore, it has been shown to stimulate cartilage synthesis in in vitro studies with chondrocytes obtained from patients suffering from osteoarthritis. These properties make rhCD-RAP a promising candidate for cartilage regeneration in indications such as chondral defects and osteoarthritis.

Previous articleScientists Revealed DNA Fingerprint for ALS Risk
Next articleAntibacterial Found to Play Antiviral Role As Well